In recent biomarker research from landmark clinical trials4,46 assessing atezolizumab plus bevacizumab therapy for patients with HCC, partial evidence was obtained for the inhibition of VEGF-mediated Treg proliferation and inhibition of myeloid cell inflammation during combined immunotherapy47. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.